Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
ABSTRACT Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW. Methods: This was a cross-section...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Pneumologia e Tisiologia
|
| Series: | Jornal Brasileiro de Pneumologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000500204&tlng=en |
| _version_ | 1819102835302727680 |
|---|---|
| author | Mariana Bueno Manini Natasha Yumi Matsunaga Lívea Gianfrancesco Marina Simões Oliveira Maria Rosa Vieira de Carvalho Gisleine Leila Martins Tengler Ribeiro Eliane de Oliveira Morais Maria Angela Gonçalves O. Ribeiro André Moreno Morcillo José Dirceu Ribeiro Adyléia Aparecida Dalbo Contrera Toro |
| author_facet | Mariana Bueno Manini Natasha Yumi Matsunaga Lívea Gianfrancesco Marina Simões Oliveira Maria Rosa Vieira de Carvalho Gisleine Leila Martins Tengler Ribeiro Eliane de Oliveira Morais Maria Angela Gonçalves O. Ribeiro André Moreno Morcillo José Dirceu Ribeiro Adyléia Aparecida Dalbo Contrera Toro |
| author_sort | Mariana Bueno Manini |
| collection | DOAJ |
| description | ABSTRACT Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW. Methods: This was a cross-sectional study involving preterm infants who received prophylaxis with palivizumab at a referral center in Brazil during the first two years of age. A structured questionnaire was administered in a face-to-face interview with parents or legal guardians. Results: The study included 410 preterm infants (median age = 9 months [0-24 months]). In the sample as a whole, 111 children (27.1%; [95% CI, 22.9-31.5]) had RW. The univariate analysis between the groups with and without RW showed no differences regarding the following variables: sex, ethnicity, maternal level of education, gestational age, birth weight, breastfeeding, number of children in the household, day care center attendance, pets in the household, and smoking caregiver. The prevalence of RW was twice as high among children with bronchopulmonary dysplasia (adjusted OR = 2.08; 95% CI, 1.11-3.89; p = 0.022) and almost five times as high among those with a personal/family history of atopy (adjusted OR = 4.96; 95% CI, 2.62-9.39; p < 0.001) as among those without these conditions. Conclusions: Preterm infants who received prophylaxis with palivizumab but have a personal/family history of atopy or bronchopulmonary dysplasia are more likely to have RW than do those without these conditions. |
| first_indexed | 2024-12-22T01:40:52Z |
| format | Article |
| id | doaj.art-fc20b36f80f4408aabd1060b6aa3ffb7 |
| institution | Directory Open Access Journal |
| issn | 1806-3756 |
| language | English |
| last_indexed | 2024-12-22T01:40:52Z |
| publisher | Sociedade Brasileira de Pneumologia e Tisiologia |
| record_format | Article |
| series | Jornal Brasileiro de Pneumologia |
| spelling | doaj.art-fc20b36f80f4408aabd1060b6aa3ffb72022-12-21T18:43:15ZengSociedade Brasileira de Pneumologia e TisiologiaJornal Brasileiro de Pneumologia1806-375610.36416/1806-3756/e20210157Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumabMariana Bueno ManiniNatasha Yumi MatsunagaLívea GianfrancescoMarina Simões OliveiraMaria Rosa Vieira de CarvalhoGisleine Leila Martins Tengler RibeiroEliane de Oliveira MoraisMaria Angela Gonçalves O. RibeiroAndré Moreno MorcilloJosé Dirceu RibeiroAdyléia Aparecida Dalbo Contrera ToroABSTRACT Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW. Methods: This was a cross-sectional study involving preterm infants who received prophylaxis with palivizumab at a referral center in Brazil during the first two years of age. A structured questionnaire was administered in a face-to-face interview with parents or legal guardians. Results: The study included 410 preterm infants (median age = 9 months [0-24 months]). In the sample as a whole, 111 children (27.1%; [95% CI, 22.9-31.5]) had RW. The univariate analysis between the groups with and without RW showed no differences regarding the following variables: sex, ethnicity, maternal level of education, gestational age, birth weight, breastfeeding, number of children in the household, day care center attendance, pets in the household, and smoking caregiver. The prevalence of RW was twice as high among children with bronchopulmonary dysplasia (adjusted OR = 2.08; 95% CI, 1.11-3.89; p = 0.022) and almost five times as high among those with a personal/family history of atopy (adjusted OR = 4.96; 95% CI, 2.62-9.39; p < 0.001) as among those without these conditions. Conclusions: Preterm infants who received prophylaxis with palivizumab but have a personal/family history of atopy or bronchopulmonary dysplasia are more likely to have RW than do those without these conditions.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000500204&tlng=enInfant, prematureRespiratory soundsAsthmaPalivizumabrespiratory syncytial virusesRespiratory hypersensitivity |
| spellingShingle | Mariana Bueno Manini Natasha Yumi Matsunaga Lívea Gianfrancesco Marina Simões Oliveira Maria Rosa Vieira de Carvalho Gisleine Leila Martins Tengler Ribeiro Eliane de Oliveira Morais Maria Angela Gonçalves O. Ribeiro André Moreno Morcillo José Dirceu Ribeiro Adyléia Aparecida Dalbo Contrera Toro Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab Jornal Brasileiro de Pneumologia Infant, premature Respiratory sounds Asthma Palivizumab respiratory syncytial viruses Respiratory hypersensitivity |
| title | Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| title_full | Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| title_fullStr | Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| title_full_unstemmed | Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| title_short | Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| title_sort | risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab |
| topic | Infant, premature Respiratory sounds Asthma Palivizumab respiratory syncytial viruses Respiratory hypersensitivity |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000500204&tlng=en |
| work_keys_str_mv | AT marianabuenomanini riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT natashayumimatsunaga riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT liveagianfrancesco riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT marinasimoesoliveira riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT mariarosavieiradecarvalho riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT gisleineleilamartinstenglerribeiro riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT elianedeoliveiramorais riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT mariaangelagoncalvesoribeiro riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT andremorenomorcillo riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT josedirceuribeiro riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab AT adyleiaaparecidadalbocontreratoro riskfactorsforrecurrentwheezinginpreterminfantswhoreceivedprophylaxiswithpalivizumab |